Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 31Gastrointestinal 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Sarcoma 160Glioblastoma 86Gliosarcoma 79Brain Neoplasms 52Central Nervous System Neoplasms 47Osteosarcoma 43Astrocytoma 40Sarcoma, Ewing 39Neoplasm Metastasis 37Melanoma 35Rhabdomyosarcoma 34Neoplasms 34Ovarian Neoplasms 33Glioma 32Neuroblastoma 30Breast Neoplasms 30Oligodendroglioma 29Lymphoma 28Recurrence 27Colorectal Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Dendritic Cell Sarcoma, Interdigitating 22Stomach Neoplasms 21Lymphoma, Non-Hodgkin 21Gastrointestinal Stromal Tumors 20Carcinoma, Renal Cell 19Sarcoma, Synovial 18Pancreatic Neoplasms 18Lymphoma, Follicular 18Neurofibrosarcoma 17

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × Sarcoma × Clear all
NCT03611868 2025-08-07

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Ascentage Pharma Group Inc.

Phase 1/2 Active not recruiting
230 enrolled
DermatologicSarcoma

Uveal Melanoma, Melanoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡